Modality
Fusion Protein
MOA
PI3Ki
Target
LAG-3
Pathway
DDR
ADHDWet AMD
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
~Nov 2020
→ ~Feb 2022
Phase 3
~May 2022
→ ~Aug 2023
NDA/BLA
~Nov 2023
→ ~Feb 2025
Approved
May 2025
→ Oct 2026
ApprovedCurrent
NCT04779773
1,899 pts·ADHD
2025-05→2026-10·Active
1,899 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2026-10-146mo awayPh3 Readout· ADHD
Trial Timeline
Q3Q42026Q2Q3Q4
Approved
Active
Catalysts
Ph3 Readout
2026-10-14 · 6mo away
ADHD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04779773 | Approved | ADHD | Active | 1899 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |